⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Official Title: A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone

Study ID: NCT01441947

Conditions

Breast Cancer

Study Description

Brief Summary: The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to prevent cancer growth. The single agent portion of this study is now closed to accrual. This research study is now examining the efficacy of cabozantinib in combination with fulvestrant for treatment of hormone-receptor-positive breast cancer that has spread to bone.

Detailed Description: Cabozantinib will be taken orally once a day in cycles of 28 days (4 weeks). Fulvestrant will be given intramuscularly on days 1 and 15 of cycle 1 and on day 1 of all subsequent cycles. On Day 1 of each cycle subjects will have the following tests and procedures: * Performance status * Physical exam * Vital signs * Routine blood samples * Blood and urine samples to look at bone markers (Cycle 1 through 6 only) Subjects will also have the following additional tests and procedures: * Tumor assessment by Computed Tomography (CT) scan and bone scan at Cycle 3, then every 12 weeks * Blood or urine pregnancy test (if applicable) on Day 1 of Cycles 1, 2, 4, then every 12 weeks * Urine sample and blood test for thyroid function (Cycle 1, 3, 5, then every 6 weeks) * Blood test for breast cancer tumor marker (Cycle 1 and 4, then every 6 weeks) * Pain questionnaire and painkiller medication diary at 7-day intervals during Week 3, Week 6, and every 6 weeks thereafter.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Contact Details

Name: Steven J Isakoff, MD, PhD

Affiliation: Massachusetts General Hospital

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: